Characteristics of renal responders
| . | Renal responders (n = 62) . | Nonresponder (n = 104) . | P . |
|---|---|---|---|
| Age, y (range) | 62.4 (50.7-73.6) | 64.5 (57.3-74.5) | ns |
| Diagnosis before 2004, n (%) | 8 (12.9) | 44 (42.3) | <.0001 |
| MIDD type, n (%) | LCDD (n = 51) | LCDD (n = 86) | ns |
| LHCDD (n = 3) | LHCDD (n = 8) | ||
| HCDD (n = 8) | HCDD (n = 10) | ||
| eGFR at diagnosis, mL/min/1.73 m2 (range) | 23.0 (12.6-36.3) | 14.4 (7.0-29.6) | .004 |
| RRT requirement at diagnosis, n (%) | 4 (6.5) | 30 (28.8) | .0006 |
| 24-h proteinuria (g) | 2.0 (0.9-4.9) | 1.5 (0.7-3.5) | ns |
| Symptomatic myeloma, n (%) | 22 (35.5) | 47 (45.2) | ns |
| dFLC at diagnosis, mg/L (range) | 1478 (146-4768) | 875 (141-2990) | ns |
| VGPR/CR, n (%) | 47 (75.8) | 42 (40.4) | <.0001 |
| Data at last follow-up | |||
| eGFR, mL/min/1.73 m2 (range) | 42.6 (26.6-58.9) | 27.2 (20.4-33.6) | .005 |
| ESRD, n (%) | 8 (12.9) | 63 (60.6) | <.0001 |
| Death, n (%) | 12 (19.4) | 58 (55.8) | <.0001 |
| Treatment received | |||
| Bortezomib-based regimen, n (%) | 51 (82.3) | 55 (52.9) | .0001 |
| No treatment, n (%) | 0 | 5 (4.8) | ns |
| . | Renal responders (n = 62) . | Nonresponder (n = 104) . | P . |
|---|---|---|---|
| Age, y (range) | 62.4 (50.7-73.6) | 64.5 (57.3-74.5) | ns |
| Diagnosis before 2004, n (%) | 8 (12.9) | 44 (42.3) | <.0001 |
| MIDD type, n (%) | LCDD (n = 51) | LCDD (n = 86) | ns |
| LHCDD (n = 3) | LHCDD (n = 8) | ||
| HCDD (n = 8) | HCDD (n = 10) | ||
| eGFR at diagnosis, mL/min/1.73 m2 (range) | 23.0 (12.6-36.3) | 14.4 (7.0-29.6) | .004 |
| RRT requirement at diagnosis, n (%) | 4 (6.5) | 30 (28.8) | .0006 |
| 24-h proteinuria (g) | 2.0 (0.9-4.9) | 1.5 (0.7-3.5) | ns |
| Symptomatic myeloma, n (%) | 22 (35.5) | 47 (45.2) | ns |
| dFLC at diagnosis, mg/L (range) | 1478 (146-4768) | 875 (141-2990) | ns |
| VGPR/CR, n (%) | 47 (75.8) | 42 (40.4) | <.0001 |
| Data at last follow-up | |||
| eGFR, mL/min/1.73 m2 (range) | 42.6 (26.6-58.9) | 27.2 (20.4-33.6) | .005 |
| ESRD, n (%) | 8 (12.9) | 63 (60.6) | <.0001 |
| Death, n (%) | 12 (19.4) | 58 (55.8) | <.0001 |
| Treatment received | |||
| Bortezomib-based regimen, n (%) | 51 (82.3) | 55 (52.9) | .0001 |
| No treatment, n (%) | 0 | 5 (4.8) | ns |
eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; ns, not significant; RRT, renal replacement therapy.